Article
Gastroenterology & Hepatology
Puja G. Khaitan, Tyler Holliday, Austin Carroll, Wayne L. Hofstetter, Erin M. Bayley, Nicolas Zhou, Sameer Desale, Thomas J. Watson
Summary: This study assessed the correlation between clinical complete response (ycCR) and pathologic complete response (ypCR) and found that current restaging tools cannot reliably predict ypCR after neoadjuvant chemoradiotherapy (nCRT). Although multimodal restaging appears to be a more accurate predictor of ypCR than any individual testing modality, ycCR cannot be relied upon to determine the need for esophagectomy.
JOURNAL OF GASTROINTESTINAL SURGERY
(2022)
Review
Oncology
Hai Guo, Hong-Tao Tang, Wen-Long Hu, Jun-Jie Wang, Pei-Zhi Liu, Jun-Jie Yang, Sen-Lin Hou, Yu-Jie Zuo, Zhi-Qiang Deng, Xiang-Yun Zheng, Hao-Ji Yan, Kai-Yuan Jiang, Heng Huang, Hai-Ning Zhou, Dong Tian
Summary: Esophageal cancer is a common and fatal malignant tumor worldwide. Neoadjuvant therapy combined with surgery is the standard treatment for locally advanced esophageal cancer. However, the efficacy of this treatment varies among patients. Currently, there is a lack of accurate and uniform criteria for evaluating efficacy after neoadjuvant therapy. Radiomics, a non-invasive image analysis method, has emerged as a promising approach for predicting efficacy and prognosis of esophageal cancer by analyzing high-throughput imaging features. In this literature review, we discuss the definition and workflow of radiomics, advances in efficacy prediction after neoadjuvant therapy, and the current application of radiomics in this field.
FRONTIERS IN ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Lucia Grana-Lopez, Tania Perez-Ramos, Fiz Andres Macineira, Angeles Villares, Manuel Vazquez-Caruncho
Summary: This study investigates the possibility of using the increase in ADC-values within the breast lesion to predict axillary complete response to neoadjuvant chemotherapy. The results suggest that adding the evaluation of tumour response using diffusion-weighted imaging can improve the prediction of axillary response to NAC.
BRITISH JOURNAL OF RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Tao Song, Qi Yao, Jinrong Qu, Hongkai Zhang, Yan Zhao, Jianjun Qin, Wen Feng, Shouning Zhang, Xianhua Han, Shaoyu Wang, Xu Yan, Hailiang Li
Summary: IVIM-DWI can be an effective functional imaging technique in predicting pathologic response to NAC in locally advanced ESCC, with significant increases in ADC, D, and f values post-NAC and higher D and Delta D values in responders compared to non-responders.
EUROPEAN RADIOLOGY
(2021)
Article
Oncology
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Summary: MDM2 amplification and TP53 status are associated with response to therapy in patients with esophageal adenocarcinoma. Worsening TP53 dysfunction is directly correlated with worse treatment outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Franco Iafrate, Fabio Ciccarelli, Giorgio Maria Masci, Damiano Grasso, Francesco Marruzzo, Francesca De Felice, Vincenzo Tombolini, Giancarlo D'Ambrosio, Fabio Massimo Magliocca, Enrico Cortesi, Carlo Catalano
Summary: This study investigated the predictive role of diffusion-weighted magnetic resonance imaging (DW-MRI) in assessing the response to total neoadjuvant therapy (TNT) in patients with locally advanced rectal cancer (LARC). The results showed that pre-treatment ADC values were significantly associated with pathological response, loco-regional downstaging after therapy, and reduction of tumor volume. ADC values could effectively differentiate between complete responders (pCR) and non-complete responders (non-pCR) with a sensitivity of 75% and specificity of 70%.
EUROPEAN RADIOLOGY
(2023)
Review
Immunology
Qing Li, Ting Liu, Zhenyu Ding
Summary: Esophageal cancer is one of the most common cancers worldwide, especially in China. Current treatment methods have limited efficacy, necessitating the exploration of new treatment strategies. Immunotherapy has emerged as a promising approach and has been shown to significantly improve survival rates in cancer patients. Combining chemotherapy and/or radiotherapy with immunotherapy may have a synergistic antitumor effect.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xiaokun Li, Siyuan Luan, Yushang Yang, Jianfeng Zhou, Qixin Shang, Pinhao Fang, Xin Xiao, Hanlu Zhang, Yong Yuan
Summary: This study aimed to explore the effectiveness of adjuvant therapy after trimodal therapy (neoadjuvant chemoradiotherapy and esophagectomy) in patients with thoracic esophageal squamous cell carcinoma (ESCC). The results showed that adjuvant therapy could reduce the overall survival (OS) and disease-free survival (DFS) in ESCC patients. It is not recommended for patients without nodal metastases after neoadjuvant therapy.
Article
Oncology
Roberta La Mendola, Maria Bencivenga, Lorena Torroni, Luca Alberti, Michele Sacco, Francesco Casella, Cecilia Ridolfi, Nicola Simoni, Renato Micera, Michele Pavarana, Giuseppe Verlato, Simone Giacopuzzi
Summary: Recurrence occurs in about one-fourth of esophageal cancer cases with pathological complete response (pCR), mainly at distant level. Local recurrences are more common in esophageal squamous cell carcinoma (SCC) cases, with the main issue being systemic disease control. SCC patients with T4 stage have an increased risk of recurrence, requiring a personalized approach in terms of adjuvant treatment and follow-up.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Review
Surgery
Yung Lee, Yasith Samarasinghe, Michael H. Lee, Luxmy Thiru, Yaron Shargall, Christian Finley, Wael Hanna, Oren Levine, Rosalyn Juergens, John Agzarian
Summary: This study aimed to analyze esophageal cancer patients who previously underwent neoadjuvant therapy followed by a curative resection to determine if additional adjuvant therapy improves survival outcomes. The study found that patients who received adjuvant therapy after surgery had a lower mortality rate compared to those who did not, but the impact on secondary outcomes remains uncertain.
Article
Surgery
Siva W. Raja, Thomas Rice, Min E. Lu, Marie H. Semple, Eugene C. Blackstone, Sudish Murthy, Usman Ahmad, Michael J. McNamara, Andrew Toth, Hemant Ishwaran
Summary: The study aimed to identify which patients with locally advanced esophageal cancer would benefit the most from additional adjuvant therapy after neoadjuvant therapy. It was found that patients with more advanced cancer, specifically those with high nodal burden and positive margins, received the most survival benefit from adjuvant therapy.
Article
Oncology
Giuseppina Arbore, Luca Albarello, Gabriele Bucci, Marco Punta, Andrea Cossu, Lorella Fanti, Aurora Maurizio, Francesco Di Mauro, Vito Bilello, Gianluigi Arrigoni, Silvia Bonfiglio, Donatella Biancolini, Francesco Puccetti, Ugo Elmore, Luca Vago, Stefano Cascinu, Giovanni Tonon, Riccardo Rosati, Giulia Casorati, Paolo Dellabona
Summary: Current treatment for locally advanced esophageal adenocarcinoma involves neoadjuvant chemotherapy (nCT) before surgery, but response rates are low. This study examines the immune mechanisms involved in nCT response and identifies potential immune signatures that could be used for personalized treatment. The results show that patients with a complete response to nCT have increased immune response and proliferation, along with specific immune cell populations and cytokine profiles. These findings suggest that baseline tumor immunity plays a crucial role in the clinical activity of nCT and could be used to stratify patients for tailored treatments.
Article
Oncology
Satoru Matsuda, Hirofumi Kawakubo, Akihiko Okamura, Keita Takahashi, Tasuku Toihata, Ryo Takemura, Shuhei Mayanagi, Hiroya Takeuchi, Masayuki Watanabe, Yuko Kitagawa
Summary: Histological response influenced long-term outcomes of patients post-NAC esophagectomy, even within same pathologic stage groups. Current risk stratification system aids in selecting appropriate candidates for adjuvant therapy.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Kazuo Narushima, Ryuichi Nishii, Shinichi Okazumi, Hideaki Shimada, Yasunori Akutsu, Takamasa Maeda, Shigeo Yasuda, Shigeru Yamada, Kiyohiko Shuto, Kentaro Tamura, Kana Yamazaki, Makoto Shinoto, Hitoshi Ishikawa, Mikito Mori, Hisahiro Matsubara
Summary: This study evaluated the clinical effectiveness of MET PET/CT in esophageal cancer patients and investigated its application in assessing early response to neoadjuvant CIRT. The results showed that MET PET/CT can clearly demonstrate esophageal cancer, and post-SUVmax was found to be the most suitable parameter. There was a correlation between the evaluated parameters and histological assessments, indicating the potential clinical utility of this method.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Seth I. Felder, Sujata Patil, Erin Kennedy, Julio Garcia-Aguilar
Summary: The study found significant inter- and intra-surgeon variation in the selection of predefined endoscopic features used for grading tumor response, as well as in selecting the tumor response grade itself. However, individual endoscopic features and tumor response grades tended to cluster together, suggesting consistency in interpretation. Surgeons were more accurate in identifying patients with a complete response compared to those with an incomplete response.
ANNALS OF SURGICAL ONCOLOGY
(2021)
